In patients with an increase in EDSS of @ or @ during relapse , natalizumab increased the probability of @-week confirmed complete recovery from relapse by @ % ( hazard ratio -LSB- HR -RSB- = @ ; P = @ ) and @ % ( HR = @ ; P = @ ) compared to placebo , respectively .